In a cohort of HNSCC patients treated with the anti-PD-1 immunotherapeutic drug pembrolizumab, the simultaneous expression of PD-L1 and PD-L2 were directly correlated with patient survival and improvement in the immunotherapeutic response (24). Here, CD274 is linked to head and neck squamous cell carcinoma.